Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469352 · ClinicalTrials.gov registry record · Phase 3
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
A Phase 3 study of Macular Degeneration, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00469352 is a Phase 3 study of Macular Degeneration that has completed, run by Oregon Health and Science University. The registered enrollment target is 150 participants, below the 173-participant average among 26 other Macular Degeneration trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00469352, a Phase 3 study of Macular Degeneration, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand whether genes or certain factors in the environment determine how eyes will respond to Lucentis (ranibizumab) treatment. For example, whether having variants within specific genes means that a patient is likely to get better vision from treatment than another patient with different genes.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Oregon
- Casey Eye Institute, Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469352
The ClinicalTrials.gov registry entry for NCT00469352 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 173-participant average among 26 other Macular Degeneration trials with a reported enrollment target (13% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00469352 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00469352 about?
NCT00469352 is a clinical study titled "A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD". The purpose of this study is to understand whether genes or certain factors in the environment determine how eyes will respond to Lucentis (ranibizumab) treatment. For example, whether having variants within specific genes means that a patient is likely to get better vision from treatment than anoth...
What is the current status of trial NCT00469352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2007-05. Estimated completion is 2010-04.
What conditions does trial NCT00469352 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT00469352?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00469352?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00469352 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
COMPLETED · Phase 3
-
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
COMPLETED · Phase 3
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.